DNA Analysis of Tumor Tissue From Patients With Acute Myeloid Leukemia
Conditions
Leukemia
Conditions: official terms
Leukemia - Leukemia, Myeloid, Acute
Conditions: Keywords
adult acute myeloid leukemia in remission, recurrent adult acute myeloid leukemia, untreated adult acute myeloid leukemia, adult acute myeloid leukemia with 11q23 (MLL) abnormalities, adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22)
Study Type
Observational
Study Phase
N/A
Study Design
N/A
Intervention
Name: DNA methylation analysis Type: Genetic
Name: comparative genomic hybridization Type: Genetic
Name: fluorescence in situ hybridization Type: Genetic
Name: microarray analysis Type: Genetic
Name: polymerase chain reaction Type: Genetic
Name: diagnostic laboratory biomarker analysis Type: Other
Name: immunologic technique Type: Other
Overall Status
Not yet recruiting
Summary
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients respond to treatment.

PURPOSE: This laboratory study is looking at tissue samples from patients with acute myeloid leukemia.
Detailed Description
OBJECTIVES:

Primary

- Determine gene expression, genome integrity, cytosine methylation, and chromatin structure in patients with normal cytogenetics leukemia (NCL) acute myeloid leukemia.

- Determine whether NCL can be deconstructed into specific disease entities by analysis of the integrated genomic and epigenomic datasets using supervised and unsupervised methods in these patients.

- Identify the gene pathways that define NCL subtypes and molecular targets for validation in preclinical and clinical trials for these patients.

- Determine whether integrated analysis provides markers of prognostic and therapeutic response that accurately predicts clinical outcome and can be used to select patients for risk-stratified therapeutic trials.

OUTLINE: This is a pilot, multicenter study.

Samples are analyzed to assess array comparative genomic hybridization using polymerase chain reaction (PCR) and fluorescent in situ hybridization; chromatin immunoprecipitations (chip) using PCR; Hpa II tiny fragment enrichment by ligation-mediated PCR (HELP) using DNA methylation analysis; and gene expression profiling.

PROJECTED ACCRUAL: A total of 32 patients will be accrued for this study.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: DISEASE CHARACTERISTICS:

- Diagnosis of acute myeloid leukemia

- Enrolled on clinical trial ECOG-E1900

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- Not specified
Location
Sponsors
Eastern Cooperative Oncology Group
Source
National Cancer Institute (NCI)
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page